`
`https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Produ...
`
`Drug Databases (https://www.fda.gov/Drugs/InformationOnDrugs/)
`
`Orange Book: Approved Drug Products
`with Therapeutic Equivalence
`Evaluations
`
`Home (index.cfm?resetfields=1) | Back to Product Details
`Additional Information about Patents
`
`• Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
`• Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed
`patents may include drug substance and/or drug product claims that are not indicated in the listing.
`• As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug
`substance and the drug product (and is eligible for listing on either basis) is required only to specify
`that it claims either the drug substance or the drug product. Orange Book users should not rely on an
`Orange Book patent listing, regardless of when first published, to determine the range of patent claims
`that may be asserted by an NDA holder or patent owner.
`
`Patent and Exclusivity for: N208144
`
`Product 001
`BRIMONIDINE TARTRATE (LUMIFY) SOLUTION/DROPS 0.025%
`
`1 of 2
`
`8/22/2022, 3:15 PM
`
`Eye Therapies Exhibit 2079, 1 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Eye Therapies Exhibit 2079, 2 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`